Keywords: Tumors, Spectroscopy, IDH mutant; gliomas; 2-hydroxyglutarate; SVS; 1H-MRSIIDH mutation has become one of the most important prognostic biomarkers in glioma management, regardless of histopathological features. The oncometabolite 2HG has been proposed as a biomarker for IDH-specific genetic profiles for gliomas. We report clinical utility of SVS and 1H-MRSI using a long TE (97 ms) in assessing IDH-mutant gliomas by detecting the characteristic resonances of 2HG. Our results from 25 patients showed sensitivity and specificity of 77% and 83%, respectively. In conclusion, 1H-MRS with optimized TE can accurately detect 2HG levels, which has significant clinical implications for determining prognosis and evaluating therapeutic efficacy for targeted and/or alternative therapies.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords